Cargando…

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

BACKGROUND: So far, clinical studies in primary progressive MS (PPMS) have failed to meet their primary efficacy endpoints. To some extent this might be attributable to the choice of assessments or to the selection of the study population. OBJECTIVE: The aim of this study was to identify outcome inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemssen, T., Rauer, S., Stadelmann, C., Henze, T., Koehler, J., Penner, I.-K., Lang, M., Poehlau, D., Baier-Ebert, M., Schieb, H., Meuth, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578855/ https://www.ncbi.nlm.nih.gov/pubmed/26393519 http://dx.doi.org/10.1371/journal.pone.0138243

Ejemplares similares

Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany
por: Becker, Veit, et al.
Publicado: (2018)

The MRZ reaction in primary progressive multiple sclerosis
por: Hottenrott, Tilman, et al.
Publicado: (2017)

Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Master’s Program
por: Voigt, Isabel, et al.
Publicado: (2021)

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
por: Abdelhak, Ahmed, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
por: Robinson, Tilman, et al.
Publicado: (2020)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Neuer Masterstudiengang: Multiple Sklerose Management
por: Voigt, Isabel, et al.
Publicado: (2022)

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis
por: Kern, Simone, et al.
Publicado: (2013)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study
por: Limmroth, Volker, et al.
Publicado: (2017)

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart(®) Injector: Results of the Prospective Cohort Study REBIFLECT
por: Rieckmann, Peter, et al.
Publicado: (2022)

Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease
por: Dimitriou, Nikolaos G., et al.
Publicado: (2023)

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study
por: Hamdy, Sherif M, et al.
Publicado: (2017)

Advances in Multiple Sclerosis 2017
por: Göbel, Kerstin, et al.
Publicado: (2018)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic
por: Wong, Jamie K, et al.
Publicado: (2023)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Symptomatic Therapy and Rehabilitation in Primary Progressive Multiple Sclerosis
por: Khan, Fary, et al.
Publicado: (2011)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

The Role of B Cells in Primary Progressive Multiple Sclerosis
por: Holloman, Jameson P., et al.
Publicado: (2021)

Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study
por: Haase, Rocco, et al.
Publicado: (2012)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis
por: Baetge, Sharon Jean, et al.
Publicado: (2021)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Visual Feedback and Postural Control in Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_55vbvobinntlj09ddjh9mgphg6